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Abstract. Dengue, a mosquito-borne viral illness caused by dengue virus types (DENV)-1 to DENV-4, is endemic
in Puerto Rico. Severe dengue usually occurs in individuals previously infected with DENV or among infants born to
previously infected mothers. To describe clinical features of dengue in infants, we retrospectively characterized dengue
patients aged < 18 months reported to the Passive Dengue Surveillance System (PDSS) during 1999–2011. To determine
frequency of signs, symptoms, and disease severity, case report forms and medical records were evaluated for patients
who tested positive for dengue by reverse transcriptase polymerase chain reaction or anti-DENV immunoglobulin
M enzyme-linked immunosorbent assay. Of 4,178 reported patients aged < 18 months, 813 (19%) were laboratory positive.
Of these, most had fever (92%), rash (53%), bleeding manifestations (52%), and thrombocytopenia (52%). Medical
records were available for 145 (31%) of 472 hospitalized patients, of which 40% had dengue, 23% had dengue with
warning signs, and 33% had severe dengue. Mean age of patients with severe dengue was 8 months. Anti-DENV immuno-
globulin G (IgG) titers were not statistically different in patients with (50%) and without (59%) severe dengue. In this study,
one-third of DENV-infected infants met the severe dengue case definition. The role of maternal anti-DENV IgG in develop-
ment of severe disease warrants further study in prospective cohorts ofmother-infant pairs.
INTRODUCTION
Dengue is a mosquito-borne disease caused by one of four
closely related dengue virus serotypes (DENV-1 through -4).1
Infection with any DENV can lead to inapparent infection,
undifferentiated acute febrile illness (AFI), dengue, or severe
dengue, including dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS).2 Severe dengue most often
occurs among patients who have been previously infected with
a DENV (i.e., secondary DENV infection).2 Children aged
< 1 year (i.e., infants) with primary DENV infection who are
born to mothers who have been previously infected with a
DENValso experience high rates of severe dengue.3 The most
common explanation for this finding is antibody-dependent
enhancement of disease (ADE), in which subneutralizing/
non-neutralizing levels of anti-DENV immunoglobulin G (IgG)
antibodies acquired from a previous DENV infection (or, in
the case of infants, from their mother in utero) bind to a differ-
ent DENV serotype but do not neutralize it. This then results
in enhanced viral uptake and infection in Fc receptor-bearing
cells, specifically mononuclear phagocytes.1,3–10 This is thought
to enable an increase in virus replication resulting in increase
in viral load, which triggers a host inflammatory response
leading to severe disease manifestations including shock due
to plasma leakage and bleeding.1,4,5,8,11
Infants are a vulnerable population in areas with endemic
dengue. They are at increased risk for DHF compared
with older children, with incidence peaking around age 6–
8 months.3,8,11,12 Compared with older children with DHF,
infants are more likely to develop medical complications,
require longer hospital stays, and succumb to the illness.11,13
However, unlike patients with DHF who are experiencing
secondary DENV infection, infants with dengue do not have
virus-specific memory B- and T-cells, and thus maternally
derived anti-DENV IgG serves as the primary protection
against DENV infection. Because the incidence of DHF and
in vitro replication of DENV in mononuclear phagocytes
obtained from ill infants both peak at age 6–8 months,3 it has
been hypothesized that ADE plays a central role in the patho-
genesis of severe dengue in infants.3
The relationship between anti-DENV IgG subclass and
dengue severity has been examined.14 Of the four subclasses,
high levels of anti-DENV IgG1 have been associated with
severe disease in adults. This IgG subclass plays an important
role in complement activation and, consequently, in the cyto-
kine cascade. Because IgG1 is the subclass most efficiently
transported between mother and fetus via the placenta and
infants have a greater proportion of anti-DENV IgG1, IgG1
may therefore participate in the mechanism of severe dengue
in infants.14–16
In Puerto Rico, infants typically have one of the highest
age-group specific incidences of dengue.17 In this report, we
describe the epidemiology of dengue among children aged
< 18 months in Puerto Rico who were reported to the island-
wide Passive Dengue Surveillance System (PDSS) and had
illness onset during January 1, 1999–December 31, 2011. We
sought to determine whether anti-DENV IgG titers and sub-
class during the acute phase of the disease were associated
with disease severity among hospitalized patients.
METHODS
Study data were obtained from PDSS, which has been
jointly operated by the Centers for Disease Control and Pre-
vention, Dengue Branch (CDC-DB) and Puerto Rico Depart-
ment of Health for > 40 years.18 All suspected dengue patients
reported to PDSS aged < 18 months and with symptom onset
during January 1, 1999–December 31, 2011 were included in
the study. For patients reported to PDSS, data including demo-
graphic information, onset date, signs and symptoms, clinical
outcomes, and clinical laboratory data are collected via the
dengue case investigation form (DCIF) (www.cdc.gov/dengue/
resources/dengueCaseReports/DCIF_English.pdf). Serum spec-
imens are submitted along with the DCIF to enable diagnostic
testing. Specimens collected ≤ 4 days after disease onset were
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tested by DENV type-specific, real-time reverse transcrip-
tase polymerase chain reaction (rRT-PCR), and specimens
collected ≥ 6 days after disease onset were tested by anti-
DENV immunoglobulin M (IgM) capture enzyme-linked
immunosorbent assay (MAC-ELISA).19,20 Specimens collected
5 days after disease onset were tested by both rRT-PCR and
MAC-ELISA.
All specimens used in the study were retested using the
above-mentioned algorithm to account for the historical dif-
ferences in testing algorithms that had been used over time.
If specimen volume permitted, anti-DENV IgG titration and
subclass testing was performed. Relative amount of anti-DENV
IgG in specimen was measured using anti-DENV IgG titration
ELISA.21 A positive anti-DENV IgG titer was defined by a
reciprocal titer > 40. The four human anti-DENV IgG sub-
classes were identified by immunoassay (PeliClass Human
IgG Subclass kit, Sanquin, Amsterdam, the Netherlands).
To more accurately classify patients using World Health
Organization (WHO, 2009) case definitions,2,22 medical records
were reviewed from all hospitalized, laboratory-positive dengue
patients aged < 18 months who were reported to PDSS during
the first 5 days after illness onset. Cases presenting during the
first 5 days after illness onset were selected for review so that
remaining specimen could be tested for the presence of anti-
DENV IgG that was likely to be maternal in origin. Medical
records were abstracted using a standardized form that
collected data including birth history, medical history since
birth, clinical course, and clinical signs and symptoms.
Definitions. A suspected dengue case is a dengue-like AFI
affecting a person for whom a health-care provider suspected
dengue and submitted a DCIF and serum specimen to PDSS.
A laboratory-positive case is a suspected dengue case for
which DENV nucleic acid was detected by rRT-PCR or anti-
DENV IgM was detected by MAC-ELISA.
A laboratory-negative case is a suspected case with no anti-
DENV IgM detected by MAC-ELISA in a specimen collected
≥ 6 days after illness onset.
A laboratory-indeterminate case is a suspected case for
which DENV nucleic acid was not detected in a specimen col-
lected in the first 5 days after illness onset and a specimen ≥
6 days after illness onset was not submitted.
Severe dengue, dengue, and warning signs of severe dengue
were defined according to 2009 WHO guidelines, and dengue
fever (DF), DHF, and DSS were defined according to 1997
WHO guidelines.2,22
Bleeding manifestations was defined as having epistaxis,
mucosal bleeding, gum bleeding, hematuria, hematemesis,
melena, hematochezia, or menorrhagia.
Statistical analysis. The frequencies of clinical, demographic,
and laboratory data were calculated for laboratory-positive
and laboratory-negative cases. Univariate and multivariate
analyses were performed to assess possible associations between
positive or negative laboratory status and symptoms of severe
dengue. Continuous variables were compared using Student’s
t test, the Mann–Whitney U test, and linear regression.
Categorical variables were evaluated using Fisher’s exact test.
Comparison of the information collected on the DCIF and
from the hospital chart of the same patient was done using the
paired Student’s t test of means and McNemar’s test for com-
parison of proportions. Relative risk was calculated using the
RelativeRisk package in R. The kappa statistic was used as a
measure of agreement between dengue definitions. P values
≤ 0.05 were considered statistically significant, and all confi-
dence intervals (CIs) were calculated at the 95% level. Data
were analyzed using STATA (STATA® Corporation, College
Station, TX), SAS® version 9.2 (SAS Institute, Cary, NC),
and R version 3.0.1 (R Foundation for Statistical Computing,
Vienna, Austria).
Ethical review. The study protocol was reviewed and
approved by the CDC’s Human Subjects Institutional Review
Board (IRB 6295, May 9, 2012).
RESULTS
Of 4,178 suspected dengue cases reported during January
1, 1999–December 31, 2011, a total of 813 (20%) were labo-
ratory positive, 737 (18%) were laboratory negative, 2,475
(59%) were laboratory indeterminate, and 153 (4%) were
unable to be tested. A slightly larger proportion of laboratory-
positive cases were male (58%) (Table 1). Patients who were
identified as a laboratory-positive case were significantly youn-
ger than those who were identified as laboratory-negative
cases (8.6 versus 10.6 months, respectively). The age distribu-
tion of laboratory-positive cases was approximately symmet-
ric with a peak at 8 months (Figure 1). Conversely, the age
distribution of laboratory-negative cases was nonsymmetrical.
Clinical signs and symptoms indicative of dengue were more
commonly reported among laboratory-positive cases than
laboratory-negative cases (Table 1). Most laboratory-positive
cases had fever (92%), rash (53%), bleeding manifestations
(52%), and thrombocytopenia (52%). Laboratory-positive
cases were two times more likely than laboratory-negative cases
to have petechiae, ecchymosis, any bleeding manifestation,
thrombocytopenia, or plasma leakage. Of interest, laboratory-
positive cases were also more likely than laboratory-negative
cases to have vomiting and diarrhea. Cough was similarly com-
mon in laboratory-positive and laboratory-negative (44% ver-
sus 48%, respectively) cases. Among the laboratory-positive
cases, there were seven fatal outcomes, compared with two
fatal outcomes among the laboratory-negative cases.
Of 472 (58%) laboratory-positive cases who were reported
to have been hospitalized, 145 (31%) had medical records
that were available and reviewed (Table 2). Of the 145 cases
who were reviewed, 41% met the 1997 WHO case defini-
tions for DF, 19% for DHF, and 4% for DSS. When using
the 2009 WHO case definitions, 40% met the case definitions
for dengue, 23% for dengue with warning signs, and 33% for
severe dengue. When compared with the data from the chart
review, the percentage of underreporting for each of these
respective classes of severe dengue based on data reported
through PDSS was 3% for DSS, 15% for DHF, and 21% for
severe dengue.
The most common warning signs of dengue among these
145 cases were pleural effusion (25%), persistent vomiting
(18%), and ascites (14%). Of those infants with severe den-
gue, 3 (6%) had severe bleeding, 25 (52%) had severe plasma
leakage resulting in shock or respiratory distress, 5 (10%) had
severe organ impairment, and 15 (31%) met the definitions
for two or more of these categories. Other clinical signs were
refusal to eat (50%), irritability (41%), constant crying (15%),
and changes in sleeping habits (8%). Severe dengue and DHF/
DSS cases presented to the hospital and were hospitalized 3.0
(95% CI = 2.5–3.6) and 2.6 (95% CI = 1.9–3.3) days post-
symptom onset, respectively; their length of hospitalization
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was similar at 7.9 (95% CI = 6.4–9.4) and 6.9 (95% CI =
5.7–8.1) days, respectively.
Cases with DHF were not more likely (relative risk ratio
[RR] = 1.1; 95% CI = 0.3–3.0) to have a positive anti-DENV
IgG titer than those not meeting criteria for DHF. Similarly,
cases with severe dengue were not more likely (RR = 1.1;
95% CI = 0.4–2.1) to have detectable anti-DENV IgG anti-
body than those not meeting criteria for severe dengue.
Anti-DENV IgG1 was found to be the most abundant sub-
class identified, followed by IgG2 (Supplemental Tables 1
and 2). Subclass of anti-DENV IgG was not significantly
associated with any classification of disease severity (data
not shown).
DISCUSSION
In examining the epidemiology of dengue among children
aged < 18 months in Puerto Rico, we found that laboratory-
positive dengue cases were significantly younger than laboratory-
negative cases. We identified several clinical features that were
TABLE 1
Demographic and clinical features of laboratory-positive and laboratory-negative dengue cases aged < 18 months reported to the Passive Dengue
Surveillance System, Puerto Rico, 1999–2011
Dengue laboratory positive Dengue laboratory negative
Difference (95% CI)N = 813 N = 737
Mean age at onset in months (95% CI)
8.6 (8.4–8.9) 10.6 (10.2–10.9) −1.9 (−2.3 to 1.5)*
N (%) N (%) Relative risk (95% CI)
Male gender 468 58 412 56 1.0 (0.9–1.1)
Fatal outcome 7 1 2 1 1.4 (1.0–2.1)
Fever 750 92 564 77 3.2 (2.3–4.4)†
Rash 428 53 167 23 2.0 (1.8–2.2)†
Petechiae 384 47 89 12 2.3 (2.0–2.5)†
Ecchymosis 69 8 6 1 1.9 (1.8–2.1)†
Bleeding manifestations‡ 419 52 96 13 2.3 (2.1–2.5)†
Thrombocytopenia 424 52 76 10 3.1 (2.7–3.6)†
Plasma leakage 105 13 22 3 1.7 (1.5–1.8)†
Shock 49 6 13 2 1.5 (1.3–1.8)†
Jaundice 17 2 5 1 1.5 (1.2–1.9)†
Vomiting 312 38 195 26 1.3 (1.2–1.5)†
Diarrhea 304 37 201 27 1.3 (1.2–1.4)†
Nasal congestion 302 37 359 49 0.8 (0.7–0.9)†
Cough 355 44 357 48 1.0 (0.9–1.1)
CI = confidence interval.
*Welch’s two-sample t test.
†P ≤ 0.05.
‡Epistaxis, mucosal bleeding, gum bleeding, hematuria, hematemesis, melena, hematochezia, or menorrhagia.
FIGURE 1. Laboratory-positive dengue cases by disease severity (both World Health Organization 1997 and 2009 case definition) based on
data reported to the passive dengue surveillance system in Puerto Rico, 1999–2011.
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more common among hospitalized laboratory-positive cases
than laboratory-negative cases. These features, which were
largely objective signs, may prove to be useful clinical indi-
cators of dengue in this preverbal age group, as the majority
of cases failed to meet case criteria for dengue. We found
that children in our population typically acquired DHF
slightly later than children in other areas with endemic den-
gue. Additionally, we found that severe dengue in this age
group was underestimated through passive surveillance.
Most studies have observed an association of severe den-
gue with infants aged 6–8 months, when maternal IgG wanes
and ADE occurs.3,8,11,12,23–25 Similarly, the mean age of DHF
and severe dengue among our population was 7.7 months and
8.6 months, respectively, and most severe dengue cases
occurred in children aged 6–10 months. The slightly wider age
range of severe dengue cases may be explained by a lower
force of infection in Puerto Rico than in areas with highly
endemic dengue. Consequently, anti-DENV IgG titers may
remain high into women’s childbearing years, resulting in their
infants being exposed to higher titers of anti-DENV IgG in
utero that are then catabolized in the infant over a longer
period of time. This could result in severe dengue occurring
slightly later in these infants.
We also observed that young children hospitalized with DHF
or severe dengue had similar rates of detection of anti-DENV
IgG antibody. Consistent with the subclass distribution of IgG
antibody passively transferred from mother to fetus via pla-
centa, anti-DENV IgG1 and IgG2 were the most abundant
subclasses identified in our study population.15,16 Moreover,
evaluating anti-DENV IgG subclass by disease severity yielded
no statistically significant associations.
A strength of this study was that we had a large number
of laboratory-positive cases, and the medical record review
allowed for a more complete description of patients’ clinical
course and consequently more accurate classification by case
definition. However, much of our retrospective study relied
on existing clinical data collected via passive dengue surveil-
lance, which can be incomplete and underestimate ultimate
severity. In addition, a limitation of this study was that anti-
DENV IgG antibody titer and subclass testing could not be
performed for half of the patients due to insufficient speci-
men volume, which is a common obstacle for this age group.9
The resulting sample size limited our ability to effectively eval-
uate anti-DENV IgG antibody titer and subclass distribution.
In addition, because our subanalysis included only patients
who were hospitalized, some selection bias may exist with
regard to the incidence of severe dengue. However, if we
were able to review medical records from all children aged
< 18 months, regardless of admission status we may expect
to find an even higher rate of severe dengue among this
cohort of young children.
We have described clinical signs and symptoms among
children aged < 18 months suspected to have dengue and
reported to PDSS. In comparing the signs and symptoms
reported to PDSS and those documented in the medical
record, we found that PDSS underestimates severity among
hospitalized laboratory-positive dengue cases. Among hospi-
talized laboratory-positive cases, we did not observe an asso-
ciation between the presence of detectable anti-DENV IgG
or IgG subclass and the occurrence of DHF and severe den-
gue. To determine the true association between maternal anti-
DENV antibody decay and onset of severe dengue in infants,
prospective studies should be conducted that follow pregnant
mothers through to birth.
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